Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman

Annals of Hematology

Volumn 83, Issue 8, 2004, Pages 495-497

  Passamonti, Francesco ^a   Rumi, Elisa ^a   Malabarba, Lucia ^a   Arcaini, Luca ^a   Orlandi, Ester ^a   Brusamolino, Ercole ^a   Pascutto, Cristiana ^a   Cazzola, Mario ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Essential thrombocythemia; Leukemia; Pipobroman; Thrombosis; Young patients

Indexed keywords

PIPOBROMAN;

ADULT; ARTICLE; BLEEDING; CAUSE OF DEATH; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG INDICATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; LIVER DISEASE; LONG TERM CARE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTHEMIA; THROMBOSIS;

EID: 4344655346     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0882-7     Document Type: Article

References (10)

1. Tefferi A, Solberg LA, Silverstein MN (2000) A clinical update in polycythemia vera and essential thrombocythemia. Am J Med 109:141-149
2. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863-866
3. Finazzi G, Ruggeri M, Rodeghiero F et al (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythmia and a high risk of thrombosis [letter]. Blood 101:3749
4. Passamonti F, Malabarba L, Orlandi E et al (2002) Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. Br J Haematol 116:855-861
5. De Sanctis V, Mazzucconi MG, Spadea A et al (2003) Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution. Br J Haematol 123:517-521
6. Murphy S, Iland H, Rosenthal et al (1986) Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol 23:177-182
7. Murphy S, Peterson P, Iland H et al (1997) Experience of Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39
8. Monto RW, Ten Pas A, Battle JD, Rohn RJ, Louis J, Louis NB (1964) A-8130 in Polycythemia J Am Med Assoc 190:97-100
9. Stein RJ (1960) Antitumor properties of N,N′-bis (3-bromopropionil) and N, N′-bis-(3-chloropropionil) piperazine. J Lab Clin Med 56:949-951
10. Ernst E, Hammerschmidt DE, Bagge U et al (1987) Leukocytes and the risk of ischemic diseases. J Am Med Assoc 257:2318-2324